MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis

Rebecca S. Cook,1,2 Kristen M. Jacobsen,3,4 Anne M. Wofford,5 Deborah DeRyckere,4 Jamie Stanford,1 Anne L. Prieto,6 Elizabeth Redente,7 Melissa Sandahl,6 Debra M. Hunter,8 Karen E. Strunk,8 Douglas K. Graham,3,4 and H. Shelton Earp III8

1Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA. 2Ingram Cancer Center, Nashville, Tennessee, USA. 3Department of Integrated Immunology and 4Department of Pediatrics, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, USA. 5Department of Psychological and Brain Science, Indiana University, Bloomington, Indiana, USA. 6Department of Pediatrics, National Jewish Health, Denver, Colorado, USA. 7Department of Pharmacology and Medicine and UNC Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

MerTK, a receptor tyrosine kinase (RTK) of the TYRO3/AXL/MerTK family, is expressed in myeloid lineage cells in which it acts to suppress proinflammatory cytokines following ingestion of apoptotic material. Using syngeneic mouse models of breast cancer, melanoma, and colon cancer, we found that tumors grew slowly and were poorly metastatic in MerTK–/– mice. Transplantation of MerTK–/– bone marrow, but not wild-type bone marrow, into lethally irradiated MMTV-PyVmT mice (a model of metastatic breast cancer) decreased tumor growth and altered cytokine production by tumor CD11b+ cells. Although MerTK expression was not required for tumor infiltration by leukocytes, MerTK–/– leukocytes exhibited lower tumor cell–induced expression of wound healing cytokines, e.g., IL-10 and growth arrest-specific 6 (GAS6), and enhanced expression of acute inflammatory cytokines, e.g., IL-12 and IL-6. Intratumoral CD8+ T lymphocyte numbers were higher and lymphocyte proliferation was increased in tumor-bearing MerTK–/– mice compared with tumor-bearing wild-type mice. Antibody-mediated CD8+ T lymphocyte depletion restored tumor growth in MerTK–/– mice. These data demonstrate that MerTK signaling in tumor-associated CD11b+ leukocytes promotes tumor growth by dampening acute inflammatory cytokines while inducing wound healing cytokines. These results suggest that inhibition of MerTK in the tumor microenvironment may have clinical benefit, stimulating antitumor immune responses or enhancing immunotherapeutic strategies.

Introduction

MerTK is a member of a receptor tyrosine kinase (RTK) family that also includes AXL and TYRO3. Family members undergo ligand-induced homodimerization, followed by catalytic tyrosine kinase activation and intracellular signaling (1–4). Cross-phosphorylation has also been demonstrated within this RTK family, suggesting heterodimerization (5). These RTKs are widely expressed in many epithelial tissues and in cells of the immune, nervous, and reproductive systems (2, 6). The MerTK ligands include growth arrest-specific 6 (GAS6) (7, 8), protein-S (9, 10), tubby and tubby-like protein-1 (TULP1) (11), and galecin-3 (12). Several of these ligands are present in serum, and all are expressed locally in some tissues. These ligands bind to the extracellular domain of MerTK, resulting in tyrosine kinase activation.

With respect to neoplastic diseases, MerTK is expressed in non-neoplastic cells found in the tumor microenvironment. MerTK is also ectopically expressed or overexpressed in many hematologic and epithelial malignant cells. Moreover, expression of MerTK and GAS6 correlates with poor prognosis or chemoresistance in some human tumor types (1, 2, 13–19). However, the mechanisms by which increased MerTK signaling contributes to tumor malignancy remain unknown.

Studies using mice devoid of MerTK revealed its critical role at the interface of innate and adaptive immunity (4, 20, 21). Innate immunity requires rapid and robust activation in response to pathogens or wounding. However, this response must be restrained to prevent inflammation-associated tissue damage or immunity against self-antigens. MerTK signaling plays a central role in dampening the innate immune response in DCs and macrophages (21). One mechanism by which MerTK performs this task is through efferocytosis, the physiological process by which apoptotic cells are engulfed by phagocytes (22). MerTK ligands, including GAS6, simultaneously bind to MerTK expressed on phagocytes and to phosphatidylserine presented on the outer plasma membrane leaflets of apoptotic cells (23, 24). This complex ligand (GAS6 bound to externalized phosphatidylserine) activates MerTK tyrosine kinase signaling, initiates phagocytosis of apoptotic material, and drives transcriptional changes that cause suppression of proinflammatory cytokines, such as IL-12, and increases in inflammatory repressors, such as IL-10 (25, 26). Therefore, MerTK-mediated efferocytosis is necessary to maintain tissue homeostasis in organs harboring abundant apoptotic materials, such as the retina and the postlactational mammary gland (27, 28).

MerTK similarly dampens TLR-induced production of proinflammatory cytokines, such as IL-6, IL-12, and type I interferons (IFNs), which fail to be downregulated in MerTK–/– mice (4, 24, 29). For example, low doses of lipopolysaccharide in MerTK–/– mice resulted in death from endotoxic shock associated with high levels of TNF-α (30). Failure to dampen acute innate immunity leads to secondary pathological activation of T and B lymphocytes directed at self-antigens (4, 26, 29, 31, 32). This is especially important...
Tumor-associated macrophages also produce immune-modulating cytokines such as IL-10, which may decrease antitumor immunity by suppressing proinflammatory cytokine expression, limiting antigen presentation, and dampening of T lymphocyte-mediated tumor cell cytotoxicity (41, 42). For example, antigen presentation in the context of increased IL-12 results in clonal expansion of CD8+ T lymphocytes (43); the suppression of IL-12 in the tumor microenvironment suggests a mechanism by which tumor-associated macrophage-mediated changes in antigen presentation and cytokine production may directly decrease T cell–mediated antitumor immunity.

Interestingly, the characteristically low IL-12/high IL-10 production observed in tumor-associated macrophages is also seen in macrophages and DCs following efferocytosis. Because MerTK appears to be a central regulator of the transition from proinflammatory to wound healing cytokine production following efferocytosis, and because MerTK-deficient macrophages produce increased proinflammatory cytokines, we tested the hypothesis that MerTK in the tumor microenvironment aids malignant tumor progression by suppressing antitumor immunity. We show here that loss of MerTK in the tumor microenvironment of MerTK–/– mice (30) slowed the establishment, growth, and metastasis of mammary tumors and melanomas in immune competent, syngeneic mice. These findings were recapitulated in spontaneous mammary tumors in recipients of MerTK–/– bone marrow transplants. Very early immune responses to syngeneic tumor cell implantation in MerTK–/– mice included decreased IL-10 and increased IL-12 production, increased leukocyte proliferation, and a higher level of tumor CD8+ T lymphocytes as compared with early tumor-induced responses in MerTK+/+ mice. Isolation of CD11b+ cells from tumors revealed MerTK-dependent repression of proinflammatory cytokines. Antibody-based depletion of CD8+ T lymphocytes restored tumor growth in MerTK–/– hosts. These results suggest that MerTK in the immune compartment of the tumor microenvironment suppresses innate immunity and promotes tumor progression. They also suggest that inhibition of MerTK signaling may produce an immunomodulatory, therapeutic benefit in some human tumors.

Results

Prolonged tumor latency and decreased metastasis in MerTK–/– hosts. To determine whether host-derived MerTK in the tumor microenvironment affects tumor formation and growth, primary mouse mammary tumor cells derived from female MMTV-PyVmT mice (43) (inbred into the C57BL/6 genetic background) were injected.
MerTK-deficient leukocytes confer tumor resistance to MerTK+/+ mice. (A) Whole cell lysates harvested from MMTV-PyVmT primary mammary tumor cells were assessed by Western analysis using antibodies indicated. Whole spleen lysates harvested from MerTK+/+ and MerTK–/– mice were used as positive and negative controls, respectively, for MerTK expression. Whole spleen lysates harvested from MerTK+/– mice were used as a positive control for AXL expression. Whole brain lysates harvested from Tyro3+/+ and Tyro3–/– mice were used as positive and negative controls from TyRO3 expression. (B–D) Bone marrow harvested from MerTK+/+ or MerTK–/– donors was delivered by tail vein injection into lethally irradiated 6-week-old female MMTV-PyVmT recipients. (B) Average tumor volume ± SEM measured in live mice by MRI at 15.8, 17.8, and 19.8 weeks of age. (C) Representative transverse MRI slices of age-matched MMTV-PyVmT recipients of MerTK+/+ or MerTK–/– bone marrow in the lower abdomen/pelvic region. The arrows indicate the location of the spine, while the tumor (T) margins are identified by the red dotted line. (D) Total tumor weight measured at 21 weeks of age (time of necropsy). Horizontal bars represent average total tumor weight ± SEM (n = 14). The P value was calculated using Student’s t test. *P < 0.05. (E) Mammary fibroblasts harvested from MerTK+/+ and MerTK–/– mice were cotransplanted with MMTV-PyVmT tumor cells into the mammary fat pads of MerTK+/+ mice, and tumor latency was measured.

Figure 2

Orthotopically into the inguinal mammary fat pads of female wild-type (MerTK+/+) and MerTK–/– recipient mice. While tumors formed in MerTK+/+ mice with an average latency of 28 days, latency was delayed in MerTK–/– littermates (P < 0.001). Tumors remained unpalpable in 70% of MerTK–/– mice throughout the entire study period of 198 days (Figure 1A). Mice carrying one functional MerTK allele (MerTK+/– mice) formed tumors with an average latency of 49 days, which was intermediate between MerTK+/+ mice (P < 0.001) and MerTK–/– mice (P < 0.001, Mantel-Cox test). This suggests that MerTK signaling in the stromal environment enhances tumor growth in a dose-dependent manner. C57BL/6-derived B16:F10 mouse melanoma cells injected orthotopically formed intradermal tumors in MerTK+/+ mice with an average latency of 26 days, compared with 48 days in MerTK–/– littermates (P = 0.0001; Figure 1A). Similarly, a third syngeneic model demonstrated prolonged latency. C57B1/6 MC38 colon cancer cells were implanted subcutaneously; in MerTK+/+ mice tumors formed with an average latency of 27 days as compared with 46 days in MerTK–/– mice (P < 0.0001, data not shown).

Histological analysis of MMTV-PyVmT tumors that formed in MerTK–/– mice revealed distinct differences from those growing in MerTK+/+ mice. Tumors harvested from MerTK+/+ mice displayed densely packed solid sheets of cells, with prominent hyperchromatic nuclei and little cytoplasm, regions of central necrosis, and invasion into skeletal muscle (Figure 1B). In contrast, tumors harvested from MerTK–/– mice were small and harbored more connective tissue as opposed to the frank cellularity of tumors in MerTK+/+ hosts (Figure 1B). MerTK–/– mice were less prone to formation of lung metastases (Figure 1C), with only 3 out of 15 MerTK–/– mice presenting with lung micrometastases derived from MMTV-PyVmT primary tumors, as compared with 13 out of 15 wild-type mice and 16 out of 17 MerTK+/+ mice exhibiting MMTV-PyVmT lung metastases. Lung metastases were not detected in any MerTK–/– mice bearing B16:F10 tumors, while 3 out of 5 wild-type mice displayed B16:F10 lung metastases. Likewise, 4 out of 5 subcutaneously implanted MC38 colon cancer cell tumors in MerTK+/+ mice yielded lung metastases, whereas none were detected in the MerTK–/– mice (Figure 1C). These data suggest that MerTK signaling in the tumor microenvironment leads to increased tumor growth and malignant progression.

MerTK–/– leukocytes confer tumor resistance in MerTK–/– mice. There are complex autocrine and paracrine interactions between tumor-associated macrophages and the epithelial cells in preclinical breast cancer models and presumably in human breast cancer. These have been well characterized in the polyoma middle T model. To rule out a potential role of MerTK in our C57Bl/6
PyVmT cells, we measured MerTK protein expression by Western analysis. Protein lysates from cultured tumor cells did not express MerTK. MerTK was detected in whole spleen lysates harvested from MerTK+/+ mice but not MerTK–/– mice (Figure 2A). Certain paracrine ligands (e.g., GAS6) might bind to other members of this RTK family in PyVmT cells; therefore, we examined the protein expression of AXL and TYRO3. Neither AXL nor TYRO3 were expressed in the PyVmT breast cancer cells. qPCR of RNA levels confirmed these findings (data not shown).

However, as MerTK is expressed in hematopoietic cells, we used bone marrow reconstitution assays to determine the impact of MerTK ablation within bone marrow–derived subpopulations of the tumor microenvironment. We harvested bone marrow from MerTK–/– × UBC-GFP and MerTK+/+ × UBC-GFP donors and delivered marrow to lethally irradiated 6-week-old C57BL/6 female transgenic MMTV-PyVmT mice. After 4 weeks, mice exhibiting >75% GFP+ hematopoietic cells were used for further analysis. At this time point (10 weeks of age), the majority of mice had already developed tumors, consistent with the published average tumor latency in this aggressive tumor model (44). Therefore, it was not feasible to detect potential differences in tumor latency. Instead, tumor growth was measured by MRI over the following 11 weeks, revealing reduced tumor volume in MerTK–/– bone marrow recipients as compared with that in MerTK+/+ bone marrow recipients (Figure 2, B and C). Similarly, upon sacrifice at the study end point (21 weeks of age), total tumor weight was decreased nearly 2-fold in MerTK–/– bone marrow recipients as compared with that in MerTK+/+ bone marrow recipients (Figure 2D). To measure the burden of apoptotic material in these tumors, immunofluorescent detection of apoptotic cells by TUNEL analysis in these late-stage tumors (19.8 weeks of age) was performed. The number of apoptotic tumor cells within F4/80+ macrophages was not altered in recipients of MerTK–/– bone marrow as compared to what was seen in tumors harvested from MerTK+/+ bone marrow recipients (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI67655DS1).

Because bone marrow–derived mesenchymal stem cells might give rise to fibroblasts in the tumor microenvironment that could modulate tumor growth and metastasis (45), we investigated the impact of MerTK–/– fibroblasts in the tumor microenvironment. 10th mammary fibroblasts harvested from MerTK–/– and MerTK+/+ donors were cotransplanted with MMTV-PyVmT tumor cells into MerTK–/– mammary fat pads. The rate of tumor formation was similar in mice receiving MerTK–/– or MerTK+/+ fibroblasts (Figure 2E). Together, these data suggest that loss of MerTK from the immune compartment, but not the fibroblast compartment, of the tumor microenvironment is sufficient to delay tumor formation.

Altered early tumor response in MerTK–/– mice. To examine early immune response in the tumor microenvironment, inguinal mammary glands were harvested 4 days after MMTV-PyVmT tumor inoculation. At this time, tumor cells were evident in the inguinal mammary glands of both MerTK+/+ and MerTK–/– mice, as shown in H&E-stained sections and by immunohistochemical detection of pan-cytokeratin (Figure 3A). However, higher-power magnification of the injection site revealed histological differences at this early stage, including an abundance of matrix deposition and reduced tumor cellularity in MerTK–/– samples as compared with that in MerTK+/+ samples (Figure 3A). After removal of the intramammary lymph node, mammary cell suspensions were stained with antibodies against CD11b and CD11c to identify tumor-recruited macrophages and DCs. To control for injection-induced changes in the cell populations, we injected sterile phospho-buffered saline (PBS) into the contralateral mammary fat pads. The results revealed that, in early-stage implanted tumors, there are differences in basal macrophage and DC levels in MerTK–/– mammary glands as compared with those in MerTK+/+ mammary glands (Figure 3B). At 4 days after tumor inoculation into the mammary gland, the percentages of macrophages and DCs were relatively unchanged in MerTK–/– mice as compared to those in PBS-injected MerTK+/+ mice. In contrast, tumor cell injection in MerTK–/– fat pads generated a >4-fold increase in macrophages and >3.5-fold increase in DCs over PBS-injected MerTK+/+ mammary glands.

RNA isolated from single cell mammary suspensions harvested at 4 days after tumor (or PBS) inoculation revealed increased transcript levels encoding the wound healing/tolerogenic cytokine IL-10 in MerTK–/– samples but not in MerTK+/+ samples (Figure 3C). Conversely, transcripts encoding the proinflammatory cytokine IL-12 were elevated 10-fold at 4 days after MMTV-PyVmT tumor cell inoculation in MerTK–/– mice but not in MerTK+/+ mice. We similarly assessed Il10 and Il12 mRNA levels 4 days following implantation of B16:F10 mouse melanoma cells into the mouse mammary fat pad. Tumor-recruited cells were collected 4 days after tumor cell injection. Il10 transcript levels were substantially increased in samples from tumor cell–inoculated MerTK–/– mice as compared with those from PBS-inoculated MerTK+/+ mice. However, Il10 transcript levels were unchanged in cells harvested from tumor cell–inoculated MerTK–/– mice (Figure 3C). While Il12 transcript levels remained relatively unchanged in MerTK–/– cells harvested from PBS- and tumor cell–treated mice, cells harvested from MerTK–/– mice expressed more Il12 transcripts 4 days after tumor cell injection as compared with 4 days after PBS injection (Figure 3C). Serum IL-12p70 and IL-6 levels were increased 4 days after intramammary MMTV-PyVmT tumor cell injection into MerTK–/– mice, but not MerTK+/+ mice, over what was seen in PBS-injected MerTK–/– and MerTK+/+ mice, respectively (Figure 3D). Mammary fat pad injection of B16:F10 tumor cells also generated increased serum IL-12p70 and IL-6 levels in MerTK–/– mice (Figure 3D). We repeated this analysis 4 days after injection of B16:F10 tumor cells i.p. into MerTK–/– and MerTK+/+ mice, yielding...
Figure 4
Altered cytokine production in MerTK−/− tumor microenvironment. (A and B) Immunohistochemistry for (A) F4/80 and (B) MerTK in tumors from (A) MerTK+/- and MerTK−/− mice and (B) MerTK+/+ mice. Original magnification, ×400 (A); ×600 (B). (C) Single cell MMTV-PyVmT tumor suspensions harvested from MerTK+/+ (solid line) and MerTK−/− (tinted area) mice were stained for CD45 and F4/80. Representative plots for live cells are shown. Average ± SEM; n = 4. (D) Total RNA harvested 4 days after PBS, MMTV-PyVmT, or B16:F10 injection was assessed by qPCR for Gas6 and Mfge8. ΔΔCT values shown represent average ± SD (n = 6) relative to PBS-injected MerTK+/+ values. **P < 0.01. (E) Serum IL-12p70 was measured by ELISA in serum harvested 3–4 weeks after tumor cell inoculation (n = 13). **P < 0.01. (F and G) CD11b+ cells were harvested from MMTV-PyVmT tumors (F) 8 weeks and (G) 15 weeks after bone marrow transplant. GFP+CD45+CD11b+ cells were purified from tumors and cell lysates were analyzed by cytokine array. *P < 0.05.
similar results. Cells harvested by peritoneal lavage were used to assess expression of transcripts encoding IL-10 and IL-12. IL10 transcripts were elevated in cells isolated from MerTK+/+ mice inoculated with B16:F10 cells by i.p. injection as compared with those in cells from MerTK−/− mice inoculated with PBS (Supplemental Figure 2). In contrast, IL10 transcripts were not elevated in MerTK+/+ mice inoculated with B16:F10 cells. Elevated IL12 transcripts were observed in peritoneal lavage cells harvested from tumor-inoculated MerTK−/− mice as compared with what was seen in PBS-inoculated mice or tumor-inoculated MerTK−/− mice. Serum IL-6 was also elevated in MerTK−/− mice inoculated i.p. with B16:F10 tumor cells (Supplemental Figure 2). We used the B16:F10 i.p. inoculation model to assess splenocyte proliferative activity. BrdU labeling of mice for 1 hour, 4 days after i.p. tumor cell or PBS inoculation, revealed that BrdU incorporation into splenocytes was similar in MerTK+/+ and MerTK−/− mice inoculated with sterile PBS and that BrdU incorporation increased in both MerTK−/− and MerTK+/+ splenocytes harvested 4 days after i.p. tumor cell injection as compared with splenocytes from PBS-injected, genotype-matched mice (Figure 3E). However, the tumor-induced increase in BrdU-positive splenocytes was substantially greater in MerTK−/− mice compared with that in tumor-treated MerTK−/− mice, suggesting that tumor-induced leukocyte proliferation was exaggerated in the absence of MerTK.

Altered tumor microenvironment in established tumors in MerTK+/+ and MerTK−/− mice. Immunohistochemical detection of F4/80, a macrophage marker, demonstrated macrophage infiltration of orthotopic MMTV-PyVmT tumors grown in MerTK+/+ and MerTK−/− mice (Figure 4A). MerTK staining was detected in B16:F10 and MMTV-PyVmT tumor macrophages grown in MerTK−/− mice (Figure 4B). To verify that MerTK−/− macrophages were capable of infiltrating spontaneously forming tumors, we generated single cell suspensions from MMTV-PyVmT mice harboring MerTK−/− and MerTK+/+ immune cells and stained cell suspensions for CD45, a cell surface marker of leukocytes, and F4/80. MerTK−/− and MerTK+/+ CD45+ leukocytes were detected at similar proportions of the total cell population (Figure 4C), revealing similar levels of CD45+ tumor leukocytes and comparable levels of MerTK−/− and MerTK+/+ tumor-associated macrophages in these established tumors.

Transcripts encoding the MerTK ligand, GAS6, were identified by qRT-PCR in RNA isolated from mammary glands 4 days after MMTV-PyVmT tumor cell injection into the mammary fat pad of MerTK+/+ and MerTK−/− mice. Gas6 levels in MerTK−/− mammary glands were >3-fold higher in tumor cell-injected glands as compared with those seen in the contralateral PBS-injected mammary gland, suggesting that GAS6 is elevated in the tumor microenvironment within 4 days (Figure 4D). Increased Gas6 mRNA levels were also detected in MerTK−/− samples harvested 4 days after B16:F10 cell inoculation, consistent with previous reports of elevated Gas6 levels in the tumor microenvironment (46). However, Gas6 remained unchanged in the MerTK−/− mice after tumor cell inoculation with MMTV-PyVmT or B16:F10 cells. Because the MerTK−/− tumor microenvironment did not induce Gas6 expression, it is possible that MerTK signaling may be part of the mechanism by which tumors upregulate GAS6 in the microenvironment. MFGE8 encodes another phosphatidylserine-interacting ligand used for efferocytosis by macrophages (47). Similar to Gas6, Mfge8 transcript levels were elevated in response to tumors in MerTK−/− but not MerTK+/+ samples (Figure 4D).

Cytokine expression in the microenvironment of established tumors was examined to determine whether the cytokine expression patterns seen 4 days after tumor cell injection were sustained. Serum IL-12p70 was measured 3–4 weeks after mammary fat pad injection of MMTV-PyVmT tumor cells. As compared with that in tumor-bearing MerTK+/+ mice, serum IL-12p70 was increased in tumor-bearing MerTK−/− mice (Figure 4E), confirming that MerTK signaling in the tumor microenvironment suppresses proinflammatory cytokine production in both early and late stages of tumor progression. To specifically assess MerTK-dependent cytokine modulation in macrophages and DCs in the tumor microenvironment, we harvested CD11b+ cells from transgenic MMTV-PyVmT mice 8 weeks after lethal irradiation and bone marrow transplant from MerTK+/+ or MerTK−/− donors. Protein lysates from CD11b+ cells were assessed by cytokine array, revealing increased levels of IL-1β, IL-6, and IL-12p40 in tumor-associated MerTK−/− CD11b+ cells as compared with levels seen in MerTK+/+ CD11b+ cells (Figure 4F). CD11b+ cells from transgenic MMTV-PyVmT mice harvested 15 weeks after bone marrow transplant revealed significantly elevated IL-6 levels in MerTK−/− tumor-associated CD11b+ cells (Figure 4G). M1- and M2-programmed tumor-associated F4/80+ macrophages were identified in situ using antibodies against inducible nitric oxide synthase (iNOS) and arginase-1 (Arg1), respectively. These results confirmed that the density of macrophages in the tumor microenvironment was relatively similar in tumors grown in MerTK−/− or MerTK+/+ bone marrow recipients. Recipients of MerTK−/− bone marrow showed a modest decrease in the ratio of M2 to M1 tumor-associated macrophages as compared with what was seen in tumors harvested from MerTK+/+ bone marrow recipients, although this trend was not statistically significant (Supplemental Figure 3). Taken together, these data demonstrate that targeted loss of MerTK from tumor-associated CD11b+ cells increases and sustains expression of proinflammatory cytokines, suggesting that MerTK signaling within tumor-associated monocye-derived cells limits the expression of proinflammatory cytokines.

CD8+ T lymphocytes are more abundant in the MerTK−/− tumor microenvironment. Four days after MMTV-PyVmT tumor cell inoculation into the mammary fat pad, mammary lymph nodes were removed and the remaining tissue was used to generate single cell suspensions. Staining for CD8 and CD4 revealed that the total CD8+CD4− population was decreased in tumor-inoculated MerTK−/− samples (Figure 5A) but remained unchanged in tumor-inoculated MerTK+/+ mice. Because NK cells express MerTK and also express CD8, we measured the relative presence of NK cells in the early tumor microenvironment by staining the CD8−CD4+ population with NK1.1. Although a slight increase in NK1.1+CD8−CD4− levels was observed in tumor-inoculated MerTK+/+ mice, this did not reach statistical significance (Figure 5B). Similar levels were seen in MerTK−/− mice treated with either PBS or with tumor cells. While these results do not rule out the impact of MerTK on tumor-infiltrating NK cell behavior, these data suggest that NK cell numbers are not greatly affected in the early tumor microenvironment by MerTK. Immunohistochemical detection of granzyme B was used to detect cytotoxic leukocytes (such as CD8+ T lymphocytes, NK cells, or NKT cells) in the tumor microenvironment of MMTV-PyVmT tumors 3–8 weeks after tumor transplant. Granzyme B–positive cells were more abundant in tumors grown in MerTK−/− mice as compared with those in tumors grown in MerTK+/+ littermates (Figure 5C). In contrast to what was seen with the CD8+CD4− population (Figure 5A), we found an early tumor-elicited increase in the CD8−CD4+ population in MerTK+/+ research article
mice but a slight decrease in MerTK+/− mice (Figure 5D). We further extended this examination for expression of CD25 to identify Tregs. Similar basal levels of CD4+CD25+ cells were identified 4 days after PBS injection into MerTK+/− and MerTK−/− mice (Figure 5E). Although levels of CD4+CD25+ cells increased in response to tumors, the increase was similar in MerTK+/− and MerTK−/− mice.

Depletion of CD8+ T lymphocytes restores tumor growth in MerTK−/− mice. CD8+ T lymphocytes were depleted from MerTK+/+ and MerTK−/− mice using antibodies against CD8. Mice were pre-treated with anti-CD8 for 1 week prior to MMTV-PyVmT tumor inoculation into mammary fat pads, and antibody treatment was maintained for 3 weeks following tumor inoculation. Tumor cell suspensions were stained with antibodies against CD4 and CD8, revealing decreased presence of CD8+CD4− cells in the tumor microenvironment of mice treated with anti-CD8 antibody, as compared with those treated with isotype-matched antibody control (Figure 5F). Histological examination revealed that, while MerTK+/− mice treated with the isotype control antibody developed small tumors comprising primarily matrix and stromal cells (Figure 5G), MerTK−/− mice treated with anti-CD8 antibodies developed larger, more aggressive tumors, with densely packed tumor epithelial cells, closely resembling the histological appearance of tumors grown in MerTK−/− mice (Figure 5G). Tumors grown in MerTK−/− mice were nearly 3-fold larger upon CD8 depletion as compared with those grown in IgG2a-treated MerTK−/− mice (Figure 5H). These data suggest that, in the MerTK−/− tumor microenvironment, CD8+ T lymphocytes are, at least in part, responsible for decreased tumor mass.

Discussion
The stromal microenvironment in which a tumor exists greatly influences its pathophysiology. Specifically, tumor-associated macrophages in human and mouse tumors have been correlated with poor prognosis and increased malignant progression. This was illustrated by studies in which targeted inhibition of CSF1 receptor signaling in tumor-associated macrophages, through gene targeting or through antibody-based pharmacologic strategies, decreased tumor growth and metastasis in mice (37, 38, 41, 48, 49). Therefore, tumor macrophages are valid therapeutic targets. Macrophages and DCs can produce the cytokines and growth factors that encourage tumor progression and metastasis, such as IL-10, which dampen antitumor immune responses (40). We demonstrate here that the MerTK+/− microenvironment responds very rapidly after tumor cell implantation by increasing production of IL-10 and GAS6 and decreasing production of IL-12. These cytokine changes are correlated with a decreased local presence of CD8+ T lymphocytes in the tumor. IL-10 and GAS6 induction in the tumor microenvironment required MerTK, as tumor-induced IL-10 and GAS6 expression was not observed in MerTK-deficient mice. This is consistent with previous data suggesting that MerTK is required in the innate immune system to induce IL-10 following efferocytosis and TLR activation (3, 4, 21, 50, 51). We also showed that MerTK-deficient cells in the tumor microenvironment express increased IL-12 and IL-6, proinflammatory cytokines known to be repressed by MerTK signaling in response to efferocytosis or TLR activation (4, 32).

Our results demonstrating upregulation of GAS6 in the tumor microenvironment of MerTK−/− mice are consistent with a previously published study, demonstrating GAS6 expression in tumor macrophages and showing that genetic loss of Gas6 in the microenvironment of syngeneic tumor transplants decreases tumor growth (46). In these studies, GAS6 was not required for tumor infiltration by macrophages; this is consistent with our finding that tumor-associated macrophage numbers are not altered by loss of MerTK. MerTK was needed for full induction of GAS6 in the tumor microenvironment, supporting a model in which MerTK signaling induces GAS6 expression in tumor macrophages, creating positive feed-forward signaling through MerTK. Sustained MerTK signaling would maintain the repression of proinflammatory cytokines and induce wound healing/tolerogenic cytokines, ultimately resulting in decreased antitumor immunity. In the PyVmT models, we have demonstrated that the GAS6 receptors MerTK, AXL and TYRO3 are absent and, thus, the production or lack of production of GAS6 is irrelevant to the tumor cell per se.

Several studies using genetic disruption of MerTK, AXL, and TYRO3 in mice demonstrated that the innate immune system responds to pathogen-mimicking agents (TLR activation) with an early increase in IL-12, IL-6, and type I IFN production, followed by MerTK, AXL-, and TYRO3-dependent reduction of proinflammatory cytokine expression, and finally with induction of wound healing and tolerogenic cytokines (IL-10, TGFB) (3, 4, 21, 50, 51). In the absence of these receptors, the innate immune system is unable to dampen expression of proinflammatory cytokines and unable to induce production of tolerogenic cytokines. Similarly, we found that early responses of the innate immune system in the MerTK−/− tumor microenvironment were characterized by damped levels of IL-12 and increased levels of IL-10. However, loss of MerTK from the tumor microenvironment caused sustained IL-12 induction (for up to 14 weeks), without induction of IL-10. Therefore, it is possible that the innate immune system uses MerTK signaling in the tumor microenvironment in a way that parallels MerTK function in wound responses.

Alternatively, MerTK in the tumor microenvironment may respond to efferocytosis. Apoptosis occurs in all tissues, and generally apoptosis rates are higher in rapidly proliferating tumors as compared with quiescent tissues. One major physiological role of MerTK is to clear apoptotic material through efferocytosis (23). To ensure that presentation of self-antigens does not stimulate autoimmunity following efferocytosis, macrophages suppress IL-12 production upon efferocytosis and induce IL-10 production (47). This limits CD8+ T lymphocyte expansion and reduces antigen presentation. It is possible that macrophage-mediated efferocytosis of apoptotic tumor cells drives the cytokine expression patterns that characterize tumor-associated macrophages. This scenario,
while not proven, would predict that modulating the consequence of chronic efferocytosis, through targeted inhibition of MerTK, would increase IL-12 levels, decrease IL-10 levels, increase tumor CD8+ T lymphocytes, and decrease malignant progression. However, this hypothesis remains to be tested, requiring a systematic evaluation of efferocytosis in the tumor microenvironment. We did not observe major differences in apoptotic material in the microenvironment of MerTK+/+ and MerTK–/– mice in late-stage tumors (Supplemental Figure 1). However, dramatic differences in apoptotic cell numbers are only seen in acute challenges in MerTK–/– mice (23). Other macrophage receptors eventually clear apoptotic material, but these alternative clearance mechanisms do not suppress the inflammatory response to the extent that MerTK does. This conclusion is substantiated by the autoimmune phenotype seen in the MerTK–/– mice.

IL-12 stimulates antitumor immunity in several models of epithelial tumors in part by promoting CD8+ T lymphocyte expansion (43). Because MerTK suppresses IL-12 production in the tumor microenvironment, MerTK signaling may suppress antitumor immunity through suppression of CD8+ T lymphocyte proliferation. Consistent with this idea, we found that depletion of CD8+ T lymphocytes restored tumor growth in the MerTK-deficient tumor microenvironment. In the case of AXL/TYRO3/MerTK triple-deficient mice, sustained IL-12 levels in normal tissues correlated with increased presence of CD8+ T lymphocytes and induction of adaptive immunity against self-antigens (21). While this response would be undesirable in normal tissues, immunity against tumor-specific antigens may improve the outcome of patients with cancer. This is supported by increasing evidence gained by expression microarrays that correlates tumors bearing a Th1 (e.g., IL-6, IL-12, CD8, granzyme B) gene expression signature with an improved outcome over tumors bearing a Th2 (e.g., IL-10, TGF-β, IL-4, cathepsin, IL-13, CD4) signature (38, 52, 53). Recent work has shown that tumors can orchestrate the immune response in a manner advantageous for tumor growth, metastasis, and escape from immune surveillance (54). The present data suggest that inhibition of MerTK signaling may be a promising therapeutic intervention that can break the deleterious immune suppression cycle by directly targeting the tumor-associated innate immune system. This could shift the immune response toward a more favorable antitumor one. MerTK inhibition that would set the stage for an antitumor Th1 response combined with new clinical agents designed to prolong antitumor T cell action may well provide an additive antitumor effect.

Methods

Mice. All mice regardless of genotype were inbred to C57BL/6 for at least 10 generations. MerTK–/– mice, originally referred to as MerKO mice, have been previously described (30). To generate MerTK+/+ and MerTK–/– littermates, MerTK–/– males and females were mated to generate the expected Mendelian ratios of offspring, which were genotyped using the following primers: forward 5′-GAATTTACCTTTCACAGGTTGCGG; reverse 5′-TCGTCACATGGCTAAGGGCG. Mice were maintained in American Association for Accreditation of Laboratory Animal Care–approved animal facilities at the University of North Carolina under an approved IACUC protocol. Where indicated, mice were treated with BrdU (10 mg/kg in sterile PBS) by i.p. injection 1 hour prior to tissue collection.

Transplantation of tumor cells. Primary mammary tumor cells were derived from a female MMTV-PyVmT mouse inbred to C57BL/6 by 6 generations as previously described (54). B16-F10 cells were obtained from American Type Tissue Culture Collection. For orthotopic injections into the mammary fat pads, 106 MMTV-PyVmT cells were resuspended in 100 μl sterile PBS (in the presence or absence of 0.5 × 106 mouse mammary fibroblasts harvested from 6-week-old virgin MerTK+/+ or MerTK–/– female C57BL/6 mice) and injected centrally in the right no. 4 inguinal fat pad of 6-week-old virgin mice. For orthotopic injections into the dermis, 105 B16.F10 melanoma cells were resuspended in 100 μl PBS and injected intradermally between the scapulae of 6-week-old mice. For subcutaneous injection, 1 × 106 MC38 colon cancer cells were injected into the flank. Tumors were detected by manual palpation. Statistical analysis of average tumor latency was assessed by log-rank test. Where indicated, i.p. injection of 3 × 108 B16.F10 cells was performed in 100 μl PBS, and cells were collected in MEM with peritoneal lavage after 4 days.

Histological analysis and immunohistochemistry. Tumors and mammary glands were harvested and immediately fixed in 10% formalin (VWR Scientific). Paraffin-embedded tumors and mammary glands were sectioned (5 μm), rehydrated, and peroxidase-quenched with 3% H2O2. Rehydrated slides were stained with H&E by the UNC Lineberger Animal Histopathology Core Facility. Immunohistochemistry was performed as previously described (55, 56) using the following polyclonal antibodies: F4/80 (6A545, Santa Cruz Biotechnology Inc.; diluted 1:200), MerTK (produced by the Earp laboratory) against a peptide in the intracellular domain of human MerTK, diluted 1:100, pan-cytokeratin (H240, Santa Cruz Biotechnology Inc.; diluted 1:500), and granyme B (Santa Cruz Biotechnology Inc.; diluted 1:200). Slides were washed in PBS and then incubated in biotinylated anti-rabbit or anti-rat antibody (Vector Laboratories) and developed using the Vectastain Kit (Vector Laboratories). Sections were photographed using the Zeiss LCM 210 microscope and Scion Image 2.0 software.

Western blot analysis. MMTV-PyVmT tumor cells were lysed in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM EDTA, 1% glycerol, and 1% Triton X-100) supplemented with phosphatase inhibitors (1 mM Na3VO4 and 0.1 mM Na2MoO4) and protease inhibitors (Complete Mini, Roche Applied Science). Whole spleen lysates harvested from MerTK+/+ and MerTK–/– mice and whole brain lysates harvested from Tyr3+/+ and Tyr3–/– mice were prepared in sodium chloride-Tris-EDTA buffer and sonicated. Whole protein lysates were separated on 8% Tris-glycine SDS-PAGE gels (Life Technologies) and then transferred to nitrocellulose membranes (iBlot, Life Technologies). Membranes were probed with primary antibodies: anti-mouse MerTK (AF591, R&D Systems; diluted 1:2,000), anti-mouse AXL (AF854, R&D Systems; diluted 1:1,000), and anti-TYRO3 rabbit sera (produced by the Prieto laboratory; diluted 1:20,000).

Bone marrow transplantation. Six-week-old female MMTV-PyVmT mice were lethally irradiated with 9.5 Gy split over 2 doses. 1 × 106 bone marrow cells from C57BL/6-Tg(UBC-GFP)30Scha/J (The Jackson Laboratory) MerTK+/+ or MerTK–/– donors were delivered to irradiated mice by tail vein injection. After 4 weeks, recipient mice that expressed ≥75% GFP in peripheral blood indicated successful engraftment and were included for further analysis. Animals were housed and experimental procedures were done in accordance with the regulatory standards approved by the University of Colorado, Anschutz Medical Campus’ IACUC.

Tumor measurement by MRI. Mammary gland tumor growth was measured over time by MRI. Mice were anesthetized with 1.5% to 2.5% inhaled isoflurane and were placed in the 4.7 Tesla Bruker MRI/MRS PharmaScan. Gadolinium-DTPA bisthmethylamide (gadodiamide, OMNISCAN) was administered intravenously as a contrast agent. Axial plane images of the animals were obtained using conventional T1-, T2-, and proton density-weighted MRI. Additional fast imaging with steady-state precession (FISP) images were required in order to exclude cysts from the tumor volume calculations, and all images were processed using Bruker Paravision software. The total tumor volume of each tumor was calculated from the resulting images by multiplying the pixel volume by the number of pixels within
the tumor area by hand-tracing the ROI with “track” command from each set of slices. All MRI acquisitions and data analysis were performed at the University of Colorado Cancer Center Animal Imaging Core.

qRT-PCR. Total RNA was isolated using RNaseasy (Qiagen) from single mammary cell suspensions and from peritoneal lavage collections. Total RNA (10 ng) was reverse transcribed with transcript-specific primers and then amplified with transcript-specific primers using SYBR Green (Invitrogen), according to manufacturer’s instructions, with a temperature of 62°C. The following primers and probes were used. Gα6, 5′-TTCTTCTCACAACCTGGCTTTGCG and 5′-GGTACGCAACATCTGCTGACCAT; mouse Il12p40, 5′-TGCCCAGCAAACTACCAAGGAC and 5′-CAGCAGATCCTAATAACACT; mouse Mmp8, forward: 5′-GGGCTTGAAGAATAAAGACGA and 5′-AGGGCCAACCTGAGACAACGA; and mouse Gapdh, 5′-AAGGACCCTTCTAGTGAC-3′ and 5′-TCCAGCACATCTACGAC-3′. The CT for each transcript within each sample was corrected for the CT of Gapdh within each sample, normalized to the CT of a single sample, and then amplified with transcript-specific primers using SyBR Green (Applied Science). Relative protein expression was analyzed on custom cytokine arrays, using an instrument that allows for color matching of Axl receptor tyrosine kinases.

Flow cytometry. Single cell suspensions of tumors or mammary glands were generated by mechanical tissue disruption using razor blades followed by 30 minutes in 1 mg/ml collagenase A (Sigma-Aldrich) in DMEM, 10% FBS, followed by 30 minutes in 0.1% collagenase I [Sigma-Aldrich] and DNaseI [EMD Millipore] at 37°C for 45 minutes) single cell suspensions, which were enriched using CD11b magnetic beads (Miltenyi Biotec) and MS Columns (Miltenyi Biotec) according to directions. Standard curves generated using manufacturer-supplied IL-12 and IL-6 were used to calculate serum concentrations of each cytokine.

Cytokine array. Whole cell lysates were prepared in lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10 mM EDTA, 10% glycerol, and 1% Triton X-100) supplemented with phosphatase inhibitors (1 mM Na3VO4 and 0.1 mM Na2MoO4) and protease inhibitors (Complete Mini, Roche Applied Science). Relative protein expression was analyzed on custom cytokine arrays, using an instrument that allows for color matching of Axl receptor tyrosine kinases.

ELISA. Serum was collected by cardiac puncture and immediately stored in frozen aliquots. Neat serum was analyzed by ELISA for mouse IL-12p70 (R&D Systems) and IL-6 (R&D Systems) according to manufacturer’s directions. Standard curves generated using manufacturer-supplied IL-12 and IL-6 were used to calculate serum concentrations of each cytokine.

Statistics. Data represent the mean ± SEM of all experiments, unless otherwise noted. Statistical significance was calculated with Mantel-Cox test (tumor latency), Student’s t test, Student’s t test with Welch’s correction for unequal variance (tumor weight, tumor volume), or analysis of variance using Prism 5 (GraphPad Software) unless otherwise noted.

Acknowledgments. This work was supported by the Breast Cancer Research Foundation (to H.S. Earp III), the UNC Breast Cancer SPORE P50 CA058223 (to H.S. Earp III), NIH R01 CA143126 (to R.S. Cook), VICC Breast Cancer SPORE P50 CA98131, and Susan G. Komen for the Cure KG100677 (to R.S. Cook). The Animal Imaging Core at University of Colorado is supported by the following grants: NCI Cancer Center P30 CA046934; NCRR CTSA UL1 RR025780. The authors thank Kendra Huber (RT MRI/CT) for her help with all MRI and data analysis.

Received for publication November 8, 2012, and accepted in revised form May 10, 2013.

Address correspondence to: H. Shelton Earp III, UNC Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, 450 West Avenue, CB 7295, 1st Floor Administration Office, Chapel Hill, North Carolina 27599, USA. Phone: 919.966.2335; Fax: 919.966.3015; E-mail: hse@med.unc.edu.


